NMBA Reversal and Postoperative Urinary Retention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

70000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-08

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing sugammadex with neostigmine (combined with a muscarinic antagonist), and postoperative urinary retention (POUR) will be evaluated. In secondary analyses, the effects of NMBA reversal strategy and POUR on costs of care and unplanned hospital visits will be analyzed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Efficacy and Safety of Sugammadex and Neostigmine

NCT04997759

Sugammadex

UNKNOWN NA

Role of Sugammadex and Neostigmine for Recovery From Rocuronium

NCT06432621

Anesthesia

ACTIVE_NOT_RECRUITING NA

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

NCT00675792

Anesthesia

COMPLETED PHASE3

Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

NCT00451217

Anesthesia, General

COMPLETED PHASE3

Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine.

NCT06982092

Perioperative Diaphragmatic Function

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Blocking Agents Urinary Retention After Procedure Urinary Retention Postoperative Neuromuscular Blockade Reversal Agent Neuromuscular Blockade Costs Atropine Sugammadex Glycopyrrolate Neostigmine Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])

The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients
* Non-urinary system surgery
* General anesthesia
* Use of rocuronium or vecuronium for neuromuscular blockade
* Neuromuscular blockade reversal with sugammadex or neostigmine (with atropine and/or glycopyrrolate)
* Postoperative admission to the post-anesthesia care unit (PACU)

Exclusion Criteria

* American Society of Anesthesiologists (ASA) physical status ≥ V
* Emergency reversal with sugammadex (≥ 16 mg/kg of sugammadex)
* Presence of foley or suprapubic catheter before or after the procedure
* Prior history of bladder resection surgery
* Observations with missing data for pre-specified confounding variables

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes